A study of ayahuasca users found a mental health pattern researchers cannot yet explain
Researchers compared first-time and experienced ayahuasca users to see how prior exposure relates to mood, stress, spirituality, substance use, and…
Category: News
Breaking health news, medical updates, policy changes, and public health developments from around the world. We deliver timely, accurate health journalism to keep you informed and aware.
Cockroaches have a reputation for surviving almost anything, but this diet proved deadly
What happens when an urban-adapted insect is fed a diet built around chips and candy? A controlled experiment offers a…
A large US study found no overall link between fluoride in pregnancy and children’s behavior
Researchers tracked prenatal exposure to public-water fluoride across 34 US states to examine whether concentrations during pregnancy were associated with…
NT-proBNP blood marker may help identify older adults at higher risk of heart disease
Share on Pinterest A NT-proBNP blood test could help indicate an increased risk of heart disease in older adults, according…
Subcutaneous tarlatamab exhibits low toxicity rates in phase 1b trial
Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell…
Phase 2 study highlights flexible dosing options for tarlatamab in relapsed SCLC
Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients…
MD Anderson trial challenges local consolidative therapy paradigm in NSCLC
Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival…
Neoadjuvant atezolizumab addition quadruples pathological responses in resectable lung tumors
Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median…
Low discontinuation rates confirm manageable safety of iza-bren
An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated…
Tumor DNA clearance reaches 39% in novel immunomodulator and ADC combination
The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in…